From: Becker's GI & Endoscopy By: Eric Oliver "Gastroenterologists continue to feel the resonating effects of the COVID-19 pandemic as they work to return operations to pre-pandemic levels, according to a report from Spherix Global Insights"...(read more).
From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in the marketplace. So far, it’s more like a ripple, according to a study of neurologists’ prescribing patterns. “The recently approved therapies will initially be niched as later-line options,” predicted Virginia R. Schobel, MSc, nephrology franchise head at Spherix Global Insights... (read more).
From: Ankylosing Spondylitis News By: Patricia Inacio, PhD. According to Spherix Global Insights' survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread use for Cimzia...(read more).
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche's Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights...(read more)
A recent survey by Spherix Global Insights showed that one-quarter of neurologists are less likely to prescribe a migraine therapy that has been on the market for less than a year due to the ongoing COVID-19 crisis
From: FiercePharma By: Beth Snyder Bulik AbbVie Prompts Patients to 'take on' Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as key advantages over Xeljanz," Piper Jaffray analyst Christopher Raymond wrote...(read more).